
Metagenomi Inc (MGX) Stock Forecast & Price Target
Metagenomi Inc (MGX) Analyst Ratings
Bulls say
Metagenomi Inc. possesses a comprehensive portfolio of innovative gene editing tools, including programmable nucleases and CRISPR-associated transposases, which contribute to its robust pipeline targeting serious genetic disorders. The company's approach has demonstrated significant efficacy, achieving durable FVIII levels of 80% in non-human primates over a 19-month period, indicating strong therapeutic potential for conditions such as Hemophilia A. Furthermore, Metagenomi's dual strategy of advancing its wholly-owned pipeline while pursuing technology out-licensing for ex vivo cell therapy enhances its growth prospects and market adaptability.
Bears say
Metagenomi reported a substantial net loss of $19.9 million for the second quarter of 2025, translating to a loss of $0.54 per share. Despite trading significantly below its cash reserves, which could suggest potential for recovery, several risks loom over the company, including possible delays in clinical advancements and the potential failure to produce positive clinical data from key programs, particularly for Hemophilia A and TTR. Additionally, the risk of long-term dilution could further exacerbate the negative outlook on the stock.
This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.
Metagenomi Inc (MGX) Analyst Forecast & Price Prediction
Start investing in Metagenomi Inc (MGX)
Order type
Buy in
Order amount
Est. shares
0 shares